Clinical Trials Browser

Neurofibroma × talimogene laherparepvec × 30 days × Clear all

NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Phase 1 Recruiting

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses